食品药品管理局批准AbbVie的Vyalev 用于治疗帕金森氏病 提供个性化剂量 FDA approves AbbVie's Vyalev for advanced Parkinson's disease, offering personalized dosing.

FDA 已批准 AbbVie 的 Vyalev （foscarbidopa/foslevodopa），这是首个 24 小时皮下输注治疗晚期帕金森病成人患者运动波动的药物。 The FDA has approved AbbVie's Vyalev (foscarbidopa/foslevodopa), the first 24-hour subcutaneous infusion treatment for motor fluctuations in adults with advanced Parkinson's disease. Vyalev在临床试验的支持下,与口服治疗相比,运动控制有了显著改善。 Supported by clinical trials, Vyalev showed significant improvements in motor control compared to oral treatments. 预计到2025年底将实现医疗保险的覆盖率。 Expected Medicare coverage is anticipated by late 2025. 这种创新疗法提供个性化剂量,加强患者症状管理。 This innovative therapy offers personalized dosing, enhancing patient symptom management.